SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mission Bio, a leader in single-cell multiomic solutions for precision medicine, announced the appointment of Brian Kim as Chief Executive Officer. With over two decades of experience in the life sciences industry, he brings a unique combination of scientific innovation and strategic business development to the company.

加利福尼亚州南旧金山（商业新闻短讯）--精准医学单细胞多组学解决方案的领导者Mission Bio宣布任命Brian Kim为首席执行官。凭借在生命科学行业20多年的经验，他为公司带来了科学创新和战略业务发展的独特结合。

His experience in driving organizational transformation and large-scale commercial growth, coupled with his deep knowledge of the life sciences sector, signifies Mission Bio’s commitment to expanding into clinical applications with biopharma partners..

他在推动组织变革和大规模商业增长方面的经验，加上他对生命科学领域的深入了解，意味着Mission Bio致力于与生物制药合作伙伴一起扩展临床应用。。

Brian's track record is a testament to his ability to create innovative customer solutions for clinical end markets and build valuable, high-growth companies. As Chief Executive Officer of Fortis Life Sciences, he founded and grew the company into a leading business-to-business provider of proprietary reagents for clinical customers.

Brian的业绩证明了他有能力为临床终端市场创建创新的客户解决方案，并建立有价值的高增长公司。作为Fortis Life Sciences的首席执行官，他创立并发展了该公司，使其成为临床客户专有试剂的领先企业对企业供应商。

As Managing Director of the Biosearch Technologies division of LGC, a UK-based private equity-backed life sciences tools company, Brian spearheaded the expansion into diagnostics and therapeutic end markets, resulting in the successful sale of the company in 2020. As President of PerkinElmer’s Life Science and Tools division, he revitalized product innovation, revamped the commercial organization, and returned the business to growth..

作为英国私人股本支持的生命科学工具公司LGC生物研究技术部的常务董事，Brian率先将业务扩展到诊断和治疗终端市场，并于2020年成功出售了该公司。作为PerkinElmer生命科学和工具部门的总裁，他振兴了产品创新，改造了商业组织，并使业务恢复增长。。

'Brian's experience in life sciences tools commercialization and clinical end markets fits exactly with Mission Bio's vision to advance single-cell multiomics into translational research and clinical applications,” said Stuart Essig, PhD, chairman of the board at Mission Bio. “He comes at an exciting stage in the company’s evolution when our technology is beginning to make measurable progress in helping improve patient health outcomes.”.

“Brian在生命科学工具商业化和临床终端市场方面的经验完全符合Mission Bio将单细胞多组学推进转化研究和临床应用的愿景，”Stuart Essig博士说，Mission Bio董事会主席。“当我们的技术开始在帮助改善患者健康状况方面取得可衡量的进展时，他正处于公司发展的一个令人兴奋的阶段。”。

'As I step into my new role, my first objective is to support the amazing team and the growing body of customer applications built around the Tapestri platform,” said Brian. “I am committed to the founding vision of establishing Mission Bio as an essential part of the new standard for personalized medicine and targeted therapies.'.

Brian说：“当我进入新角色时，我的第一个目标是支持Tapestri平台上令人惊叹的团队和不断增长的客户应用程序。”。“我致力于建立Mission Bio作为个性化医疗和靶向治疗新标准的重要组成部分的创始愿景。”。

About Mission Bio

关于Mission Bio

Mission Bio is a leading life science company, specializing in the advancement of single-cell DNA and multiomic analysis. The company’s Tapestri Platform is unique in its capabilities, offering an unparalleled level of granularity and precision that is critical for complex research areas such as cancer studies, pharmaceutical development, and advanced cell and gene therapies.

Mission Bio是一家领先的生命科学公司，专门从事单细胞DNA和多组学分析的发展。该公司的Tapestri平台功能独特，提供无与伦比的粒度和精确度，这对于癌症研究、药物开发以及先进的细胞和基因治疗等复杂研究领域至关重要。

Unlike traditional methods such as bulk sequencing, Tapestri provides a level of precision that opens the door for more tailored and effective treatment strategies. Researchers globally depend on Tapestri to identify rare cell populations, understand mechanisms of therapeutic resistance and response, and establish key quality metrics for next-generation medical treatments.

与批量测序等传统方法不同，Tapestri提供了一定程度的精确度，为更定制和有效的治疗策略打开了大门。全球研究人员依靠Tapestri来识别稀有细胞群，了解治疗抵抗和反应的机制，并为下一代医学治疗建立关键的质量指标。

Founded in 2014, Mission Bio has secured investment from firms including Mayfield Fund, Novo Growth, Cota Capital, and Agilent Technologies. With the Tapestri Platform, Mission Bio is setting the standard in the field, contributing significantly to the progress of personalized medicine and targeted therapies.

Mission Bio成立于2014年，已获得梅菲尔德基金（Mayfield Fund）、Novo Growth、Cota Capital和安捷伦科技（Agilent Technologies）等公司的投资。凭借Tapestri平台，Mission Bio正在该领域树立标准，为个性化医疗和靶向治疗的进步做出了重大贡献。

To learn more about Mission Bio and the Tapestri Platform, please visit missionbio.com..

要了解更多有关missionbio和Tapestri平台的信息，请访问missionbio.com。。